<DOC>
	<DOCNO>NCT00910247</DOCNO>
	<brief_summary>This long term , open-label , safety extension study subject partial onset seizure .</brief_summary>
	<brief_title>Eslicarbazepine Acetate Monotherapy Long Term Study</brief_title>
	<detailed_description>This long term , multicenter , open-label , safety extension study subject partial onset seizure complete , discontinue , exit 18-week treatment phase Protocols 093-045 093-046 . The initial study duration 1 year option continue study drug treatment post 1 year subject discontinues study , study drug becomes clinically available subject 's locale , sponsor terminates study drug clinical development program . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Subject Inclusion/ Subject complete , exit , discontinue reason safety 18week treatment phase Protocols 093045 093046 willing continue participation study eligible . Subject must complete least first 3 week 18week doubleblind treatment period Protocols 093045 093046 eligible . Subject must give write informed consent prior participation study . For subject &lt; 18 year age , informed consent must sign subject 's parent legal guardian , , appropriate and/or require state local law , minor subject must give write informed assent prior participation study . All subject must sign privacy authorization form , applicable . All female child bear potential ( â‰¤65 year age ) must also sign `` Women Childbearing Potential '' Addendum . Subjects must , opinion Investigator ( consultation Medical Monitor appropriate ) , continue potentially benefit continued study participation new medical condition would preclude study participation . If female subject , must continue accept method birth control define Protocols 093045 093046 duration study well Criterion Continuation Post 1 year Part Study : For subject continue post 1 year part study , subject must , opinion Investigator ( consultation Medical Monitor , appropriate ) , continue potentially benefit continued study participation new medical condition would preclude study participation .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Seizures</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Anticonvulsant</keyword>
	<keyword>Monotherapy</keyword>
	<keyword>Epilepsy simple complete partial onset seizure</keyword>
</DOC>